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EDITORIAL
Treatment of Choice for Stage I Non-small Cell Lung
Cancer: Surgery or Radiotherapy?
Hisao Asamura, MD
The textbook description on the treatment of choice for stage I non-small cell lungcancer (NSCLC) has been surgery with or without adjuvant chemotherapy.1 In
NSCLC, surgery still remains as a mainstay treatment that covers patients with stage I, II,
and selected IIIA diseases. According to a recent report on a large Japanese contempo-
raneous series of 6644 patients, the 5-year survival rates for resected stages IA and IB
were 72.0 and 49.9% in a clinical setting and 79.5 and 60.1% in a pathological setting.2
The operative risk (morbidity and mortality) has also been minimized in the last few
decades, probably because of adequate patient selection and evaluation. According to
American patterns of surgical care study data, the overall mortality rate was reported at
5.2%, and rates of 3.2% for high-volume hospitals and 4.5% for lobectomy were also
shown.3 Our recent institutional data in Tokyo also demonstrated an improved mortality
rate at 0.5%, and this was closely related to the extent of pulmonary resection, in which
a higher mortality rate was shown for pneumonectomy (3.9%) compared with lobectomy
(0.3%).4 Because of the significant difference in survival between two subgroups of stage
I disease (IA and IB), a postoperative systemic chemotherapy has been considered and
tested for stage IB disease in a clinical trial setting. Nevertheless, the preliminary results
of the most recent study (CALGB 9633) in which a combination regimen of carboplatin
and paclitaxel was postoperatively administered failed to prove the significant improve-
ment of overall survival.5 The updated meta-analysis also confirmed the limited value of
adjuvant chemotherapy in stage IB.6 These results do not mandate the routine use of
postoperative chemotherapy for stage IB patients.
On the other hand, with the advent of new, sophisticated technology for radiother-
apy, reports describing better local control and improved survival are accumulating. The
development of three-dimensional conformal radiotherapy and stereotactic body radiation
therapy (SBRT) allows precise targeting and delivery of radiotherapy. These systems
allow reduction of treatment volumes, which enable hypofractionation with markedly
increased daily doses and significantly reduced overall treatment time. SBRT combines
multiple-beam angles to achieve sharp-dose gradients, high-precision localization, and a
high dose per fraction. As a result, a highly effective biological dose can be delivered to
the target, with normal-tissue toxicities minimized. Several studies have reported signif-
icantly improved local control and survival using SBRT in patients with stage I lung
cancer. One of the largest series describing the results of SBRT was a Japanese
multi-institutional, retrospective study.7 Patients with stage I NSCLC (n  245) were
treated with hypofractionated, high-dose SBRT in 13 institutions. During follow-up
(median 24 months), the local recurrence rate was 14.5% (9.7% for T1 tumors and 20.0%
for T2 tumors). Obviously, local control in larger tumors and in lower biologically
effective doses was significantly worse. The article by Graham and colleagues in the
present issue discusses the comparison of prognoses between two cohorts of patients:
surgical patients included in a patterns-of-care study undertaken in two discontinuous
years, and radiation patients treated in SGH.6,8 They conclude that modern radiotherapy
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is a reasonable option for patients to consider for stage I
NSCLC, and they recommend this option, rather than sup-
portive care or observation, for medically inoperable patients.
These provisional data suggest the usefulness of SBRT
for stage I NSCLC, at least in medically inoperable patients
and, possibly, in medically operable patients. If so, the
thoracic oncology community must answer the following
questions. Is SBRT at least equivalent or possibly superior to
surgery in terms of local control and overall survival? What
is the morbidity/mortality for SBRT? Are they more or less
comparable with those of surgery? Is lung function preserved
by SBRT?
The most important issue—the equivalence or superi-
ority (inferiority) between SBRT and surgery—could not be
answered without direct comparison via well-planned clinical
trials. Consequently, does the present situation mean that we
are ready to perform a randomized phase III trial between
SBRT and surgery in stage I NSCLC? Can the present data
justify incorporating patients into randomized trials?
Looking at the previous reports in this context, the
following issues should be addressed. The patients who
respond well to and subsequently benefit from SBRT have
not been well characterized. For example, we do not know
exactly which population in stage I can potentially benefit
from SBRT. Furthermore, even for the largest Japanese
series, the median follow-up period was limited to 24 months
(7–78 months), and the average follow-up period in other
reports was also around 11 to 43 months. That is, the
follow-up periods in the most of the SBRT studies have not
been long enough. Looking at the survival curves of stage I
NSCLC, the tumor recurrence and subsequent patient loss
continue even after 5 years after surgery.2 Therefore, the local
recurrence rate and overall survival data reported thus far
should be considered incomplete, and we should consider that
we do not have sufficient evidence regarding these issues.
The difficulty in the radiological follow-up of irradiated
patients should be also addressed. After the shrinkage of the
tumor mass, the optimal radiological methods for detecting
the residual tumor and tumor regrowth after the completion of
radiation have never been established. Although the fol-
low-up might use a combination of positron emission tomo-
graphic and computed tomographic scans, the criteria indi-
cating a tumor biopsy to see the residual tumor have not been
clearly defined. The adequate interval of follow-up computed
tomographic and positron emission tomographic scans as
well as the radiologic findings indicating actual tumor re-
growth must be future points of discussion.
Finally, in terms of clinicopathological features, we
must be aware of of lymph-node metastasis of resected stage
I NSCLC. The accumulated data of the removed lymph nodes
in stage I patients demonstrated that even for this localized
stage, the latent metastasis was documented in 10 to 20% of
the patients who had the resection.9 The targeted radiotherapy
focusing on solely the main tumor might miss the occult
(preclinical) mediastinal metastasis and cause locoregional
recurrence.
In summary, the present data on SBRT do not allow for
immediate, direct comparison with surgery, even in a clinical
trial setting. However, we should also take advantage of the
promising features of such new technology and make use of
the data in a collaborative way. Surgeons in charge of patients
with early-stage lung cancer should have the flexibility to
perform a randomized trial while the paradigm is shifting.
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